274 related articles for article (PubMed ID: 21519259)
1. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy in adult soft tissue sarcoma.
Jain A; Sajeevan KV; Babu KG; Lakshmaiah KC
Indian J Cancer; 2009; 46(4):274-87. PubMed ID: 19749457
[TBL] [Abstract][Full Text] [Related]
4. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
6. New targets for therapy of sarcoma.
Magenau JM; Schuetze SM
Curr Opin Oncol; 2008 Jul; 20(4):400-6. PubMed ID: 18525335
[TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
9. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors in sarcomas.
Okuno S
Curr Opin Oncol; 2006 Jul; 18(4):360-2. PubMed ID: 16721131
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
[TBL] [Abstract][Full Text] [Related]
14. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.
Gamie Z; Kapriniotis K; Papanikolaou D; Haagensen E; Da Conceicao Ribeiro R; Dalgarno K; Krippner-Heidenreich A; Gerrand C; Tsiridis E; Rankin KS
Cancer Lett; 2017 Nov; 409():66-80. PubMed ID: 28888998
[TBL] [Abstract][Full Text] [Related]
15. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in development for pediatric sarcomas.
Hughes DP
Curr Opin Oncol; 2009 Jul; 21(4):332-7. PubMed ID: 19444103
[TBL] [Abstract][Full Text] [Related]
17. Targeting insulin-like growth factor 1 receptor in sarcomas.
Scotlandi K; Picci P
Curr Opin Oncol; 2008 Jul; 20(4):419-27. PubMed ID: 18525338
[TBL] [Abstract][Full Text] [Related]
18. Opportunities for improving the therapeutic ratio for patients with sarcoma.
Wunder JS; Nielsen TO; Maki RG; O'Sullivan B; Alman BA
Lancet Oncol; 2007 Jun; 8(6):513-24. PubMed ID: 17540303
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Hartmann JT; Patel S
Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
[TBL] [Abstract][Full Text] [Related]
20. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
